within Pharmacolibrary.Drugs.A_AlimentaryTractAndMetabolism.A16A_OtherAlimentaryTractAndMetabolismProducts.A16AX20_Lonafarnib;
model Lonafarnib 
   extends Pharmacolibrary.Drugs.ATC.A.A16AX20;

  annotation(Documentation(
    info ="<html><body><p>Lonafarnib is a farnesyltransferase inhibitor primarily indicated for the treatment of Hutchinson-Gilford Progeria Syndrome (HGPS). It is also under investigation for other progeroid laminopathies. The drug is orally administered and it is approved by the FDA for pediatric and adult patients with HGPS.</p><h4>Pharmacokinetics</h4><p>Pharmacokinetic parameters in children and young adults (median age 10.6 years, range 2.7–22.5 years) with Hutchinson-Gilford Progeria Syndrome (HGPS) following steady-state oral administration. Data extracted from multiple-dose (115 mg/m^2 twice daily with food) studies.</p><h4>References</h4><ol><li><p>Koh, C, et al., &amp; Heller, T (2015). Oral prenylation inhibition with lonafarnib in chronic hepatitis D infection: a proof-of-concept randomised, double-blind, placebo-controlled phase 2A trial. <i>The Lancet. Infectious diseases</i> 15(10) 1167–1174. DOI:<a href=&quot;https://doi.org/10.1016/S1473-3099(15)00074-2&quot;>10.1016/S1473-3099(15)00074-2</a>  PUBMED:<a href=&quot;https://pubmed.ncbi.nlm.nih.gov/26189433/&quot;>https://pubmed.ncbi.nlm.nih.gov/26189433</a></p></li><li><p>Zhu, Y, et al., &amp; Cutler, DL (2007). Effect of food on the pharmacokinetics of lonafarnib (SCH 66336) following single and multiple doses. <i>International journal of clinical pharmacology and therapeutics</i> 45(10) 539–547. DOI:<a href=&quot;https://doi.org/10.5414/cpp45539&quot;>10.5414/cpp45539</a>  PUBMED:<a href=&quot;https://pubmed.ncbi.nlm.nih.gov/17966839/&quot;>https://pubmed.ncbi.nlm.nih.gov/17966839</a></p></li><li><p>Wong, NS, et al., &amp; Hurwitz, HI (2011). A phase I multicenter study of continuous oral administration of lonafarnib (SCH 66336) and intravenous gemcitabine in patients with advanced cancer. <i>Cancer investigation</i> 29(9) 617–625. DOI:<a href=&quot;https://doi.org/10.3109/07357907.2011.621912&quot;>10.3109/07357907.2011.621912</a>  PUBMED:<a href=&quot;https://pubmed.ncbi.nlm.nih.gov/22011284/&quot;>https://pubmed.ncbi.nlm.nih.gov/22011284</a></p></li></ol></body></html>",
    revisions = "<html><body><ul><li>06/2025 model generated by LLM gpt-4.1, references by scholarly and scripts created by Tomas Kulhanek</li></ul></body></html>",
    experiment(StartTime = 0, StopTime = 86400, Tolerance = 1e-09, Interval = 1)
  ));  
end Lonafarnib;
